| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2023 | 131.66% | Wedbush | $2 → $3 | Upgrades | Neutral → Outperform |
| 08/09/2023 | 146.33% | BMO Capital | $3.15 → $3.19 | Maintains | Market Perform |
| 03/28/2023 | 54.44% | Mizuho | $4 → $2 | Maintains | Neutral |
| 01/06/2023 | 147.1% | BMO Capital | $2.6 → $3.2 | Maintains | Market Perform |
| 11/14/2022 | 100.77% | BMO Capital | $3 → $2.6 | Downgrades | Outperform → Market Perform |
| 11/10/2022 | — | JP Morgan | Downgrades | Overweight → Underweight | |
| 07/11/2022 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 07/11/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 07/07/2022 | 54.44% | Jefferies | $12 → $2 | Downgrades | Buy → Hold |
| 07/07/2022 | 131.66% | BMO Capital | $9 → $3 | Maintains | Outperform |
| 07/07/2022 | 517.76% | BTIG | $16 → $8 | Maintains | Buy |
| 07/07/2022 | 54.44% | Wedbush | $6 → $2 | Downgrades | Outperform → Neutral |
| 07/07/2022 | 170.27% | Barclays | $7 → $3.5 | Maintains | Overweight |
| 07/07/2022 | 208.88% | Mizuho | $16 → $4 | Downgrades | Buy → Neutral |
| 07/07/2022 | 15.83% | Piper Sandler | $10 → $1.5 | Downgrades | Overweight → Neutral |
| 06/24/2022 | 594.98% | BMO Capital | → $9 | Initiates Coverage On | → Outperform |
| 03/02/2022 | 594.98% | JP Morgan | $10 → $9 | Maintains | Overweight |
| 01/18/2022 | 440.54% | Barclays | → $7 | Upgrades | Underweight → Overweight |
| 12/22/2021 | 749.42% | HC Wainwright & Co. | $12 → $11 | Maintains | Buy |
| 11/15/2021 | 1135.52% | BTIG | → $16 | Initiates Coverage On | → Buy |
| 05/28/2021 | 440.54% | Barclays | $9 → $7 | Downgrades | Equal-Weight → Underweight |
| 03/29/2021 | 981.08% | JP Morgan | → $14 | Initiates Coverage On | → Overweight |
| 03/23/2021 | — | Jefferies | Upgrades | Hold → Buy | |
| 09/22/2020 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 06/01/2020 | 672.2% | Jefferies | $16 → $10 | Downgrades | Buy → Hold |
| 05/14/2020 | 826.64% | HC Wainwright & Co. | $16 → $12 | Maintains | Buy |
| 05/08/2020 | 1135.52% | HC Wainwright & Co. | $14 → $16 | Reiterates | → Buy |
| 03/24/2020 | — | Wedbush | Upgrades | Neutral → Outperform | |
| 02/28/2020 | 1058.3% | Nomura | $22 → $15 | Maintains | Buy |
| 11/20/2019 | 1135.52% | Guggenheim | → $16 | Initiates Coverage On | → Buy |
| 11/11/2019 | 517.76% | Wedbush | $25 → $8 | Downgrades | Outperform → Neutral |
| 06/13/2019 | 1135.52% | Mizuho | → $16 | Initiates Coverage On | → Buy |
| 06/03/2019 | 1676.06% | Cantor Fitzgerald | $21 → $23 | Reiterates | → Overweight |
| 05/14/2019 | — | Cantor Fitzgerald | Initiates Coverage On | → Overweight | |
| 03/11/2019 | — | Barclays | Initiates Coverage On | → Overweight | |
| 02/27/2019 | 1830.5% | Wedbush | $35 → $25 | Maintains | Outperform |
| 12/14/2018 | — | Goldman Sachs | Upgrades | → Buy | |
| 11/26/2018 | — | Piper Sandler | Initiates Coverage On | → Overweight |
What is the target price for CytomX Therapeutics (CTMX)?
The latest price target for CytomX Therapeutics (NASDAQ: CTMX) was reported by Wedbush on November 8, 2023. The analyst firm set a price target for $3.00 expecting CTMX to rise to within 12 months (a possible 131.66% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CytomX Therapeutics (CTMX)?
The latest analyst rating for CytomX Therapeutics (NASDAQ: CTMX) was provided by Wedbush, and CytomX Therapeutics upgraded their outperform rating.
When is the next analyst rating going to be posted or updated for CytomX Therapeutics (CTMX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CytomX Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CytomX Therapeutics was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
Is the Analyst Rating CytomX Therapeutics (CTMX) correct?
While ratings are subjective and will change, the latest CytomX Therapeutics (CTMX) rating was a upgraded with a price target of $2.00 to $3.00. The current price CytomX Therapeutics (CTMX) is trading at is $1.30, which is out of the analyst's predicted range.